A growing body of literature shows that when GLP-1 receptor agonists are administered, there are decreased levels of pro-inflammatory cytokines that are normally seen in the pathogenesis of many inflammatory diseases
But theyre not meant to be a long-term solution when FDA-approved options are available
Ideally, the prescriber is someone you can work with long term, says John Morton, MD, MPH, chief of Bariatric and Minimally Invasive Surgery at Yale Medicine and a board-certified obesity medicine specialist
[Its been] an interesting journey, said Knudsen
GLP-1 receptor agonists in PD Approved treatments for PD target dopaminergic neurotransmission, with levodopa representing the mainstay of treatments augmenting dopamine production and alleviating motor symptoms [6]
Well look next at how these benefits translate into everyday tolerability profiles